Keywords: schering, ag, kicks, off, enrollment, ph, ii

Schering AG kicks off enrollment for Ph II NSCLC trial

Article | 07 March 2005

Print This

Schering AG of Germany has commenced recruitment of patients for a Phase II clinical trial of its angiogenesis inhibitor candidate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in